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1. Introduction
Antibiotic resistance among clinical isolates of Klebsiella pneumoniae, Pseudomonas aeruginosa,
Acinetobacter baumannii, Escherichia coli, Enterobacter spp and Proteus spp is causing worldwide
concern [1-5] especially when mediated by transferable genetic elements.
The role of the Clinical Microbiology Department in this regard is crucial for the isolation of
non-susceptible bacteria and the detection of the underlying mechanisms leading to their
resistant phenotype. Rapid and reliable results are of the utmost importance in order to apply
the appropriate treatment and to contain the spread of resistance determinants within hospital
settings.
In the present chapter, laboratory procedures for the detection of antibiotic resistance mecha‐
nisms will be discussed focusing mainly on those more frequently used for Gram negative
clinical isolates around the world.
2. Antibiotic resistance mechanisms among Gram negative nosocomial
pathogens
Antibiotic resistance may be intrinsic (the microorganism is by definition resistant against a
certain antibiotic) or acquired. Acquired refers to resistance that is a consequence of mutational
events or gene acquisition via horizontal gene transfer.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Four general mechanisms leading to acquired antibiotic resistance have been described: (1)
decreased entrance of the antibiotic into the bacterial cell; (2) increased extrusion of the
antibiotic by bacterial efflux systems; (3) mutational modification of the antibiotic’s target and;
(4) production of antibiotic-inactivating enzymes. Characteristic examples for each mechanism
are presented in Table 1.
Mechanism Examples
Decreased permeability Diminished expression or loss of the OprD porin in Pseudomonas aeruginosa and
OmpK35, OmpK36 porins in Klebsiella pneumoniae [6-9]
Efflux Overexpression of MexAB-OprM and MexXY-OprM in Pseudomonas aeruginosa and
OqxAB in Klebsiella pneumoniae [10-13]
Target modification Mutations of gyrases and topoisomerases leading to fluoroquinolone resistance
[14-16]
Inactivating enzymes Production of beta-lactamases and aminoglycoside modifying enzymes [17-19]
Table 1. Examples of antibiotic resistance mechanisms.
Among the aforementioned mechanisms, the production of beta-lactamases is considered of
major importance because these enzymes are commonly transferable and inactivate multiple
beta-lactam antibiotics. Within this large enzymatic family, carbapenemases (class B metallo-
beta-lactamases (MBLs) [20] that contain zinc in their active center and class A KPC [21])
hydrolyze in vitro all or almost all beta-lactams, including carbapenems [22]. Class A extended
spectrum beta-lactamases (ESBLs) hydrolyze penicillins, monobactams and cephalosporins
whereas are inhibited by the beta-lactamase inhibitors [23,24]. Class C cephalosporinases
(AmpC) present various spectrums of cephalosporin hydrolysis but are not inhibited by the
beta-lactamase inhibitors [25]. Additionaly, AmpC enzymes may be inducible in Serratia spp,
Pseudomonas spp, Indole-positive Proteus, Citrobacter spp and Enterobacter spp (SPICE group
of bacteria) complicating the treatment of infections caused by these pathogens. Finally,
molecular class D beta-lactamases (OXA) comprise numerous enzymes with variable spec‐
trums of beta-lactam hydrolysis [26].
3. Phenotypic tests
Phenotypic tests may be used in the everyday laboratory practice in order to identify the
presence of acquired resistance mechanisms among frequently isolated nosocomial pathogens.
In the present chapter, the procedure and the interpretation of seven useful phenotypic tests
are described. Special attention has been given to the phenotypic detection of beta-lactamases
and especially those hydrolyzing carbapenems together with other beta-lactams (carbapene‐
mases).
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3.1. Double Disc Synergy Test (DDST)
The DDST is used for the detection of beta-lactamases that are inhibited by beta-lactamase
inhibitors such as clavulanic acid (Ambler class A beta-lactamases and especially ESBLs). For
SPICE organisms, cloxacillin should be incorporated in Mueller-Hinton agar during its
preparation in order to prevent any AmpC interference [27].
3.1.1. Procedure
Figure 1. Double Disc Synergy Test preparation.
Step 1: Prepare agar plates containing 200μg/ml cloxacillin (by adding 1ml solution containing
80 mg cloxacillin in 399 ml Mueller-Hinton agar at the liquid phase). Omit this step when
testing non-SPICE bacteria.
Step 2: Make a 0.5 McFarland bacterial suspension.
Step 3: Inoculate with a sterile cotton swab and place an amoxicillin/clavulanic acid disc at the
center of the plate (20 μg amoxicillin+10 μg clavulanic acid).
Step 4: Place ceftazidime, imipenem, ceftriaxone, cefotaxime, aztreonam and cefepime discs
around the central amoxicillin/clavulanic acid disc (Figure 1).
Step 5: Incubate at 37oC for 18-24h.
3.1.2. Interpretation
The DDST is considered positive when the inhibition zone of any of the antibiotics is larger
towards the clavulanic acid disc (Figure 2-lower left plate) or a ghost inhibition zone appears
between the central disc and any of the other antibiotics (Figure 2-lower right plate). This is
happening because of the ESBL’s inhibition by the clavulanic acid. In proximity to the central
disc the enzyme’s activity is blocked. Thus, the growth inhibition zone appears only towards
the clavulanic acid disc. If resistance to cephalosporins is not due to ESBL production, the test
results negative (Figure 2-upper plates).
Phenotypic and Molecular Methods for the Detection of Antibiotic Resistance Mechanisms in…
http://dx.doi.org/10.5772/57582
141
Figure 2. Interpretation of the DDST. (-): Negative; (+): Positive.
3.2. Imipenem-EDTA synergy test
EDTA (ethylene-diamine-tetraacetic acid) is a polyamino carboxylic acid that binds metal ions
like zinc and can inactivate the metallo-beta-lactamases. Therefore, it is used for the phenotypic
detection of MBL production in clinical isolates [28].
3.2.1. Procedure
Step 1: Soak paper discs within a 0.1 M EDTA solution.
Step 2: Make a 0.5 McFarland bacterial suspension.
Step 3: Inoculate with a sterile cotton swab and place an imipenem and a ceftazidime disc at
the center of the plate.
Step 4: Place the EDTA discs at both sides in respect to the antibiotics as shown in Figure 3.
Step 5: Incubate at 37oC for 18-24h.
Figure 3. Preparation of the imipenem-EDTA synergy test.
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3.2.2. Interpretation
The imipenem-EDTA synergy test is positive when the inhibition zone takes a characteristic
keyhole shape because of the MBL inactivation by the EDTA (Figure 4). In proximity to the
EDTA discs, the hydrolytic activity of MBLs is blocked. Consequently, imipenem and cefta‐
zidime inhibition zones may appear larger towards the EDTA discs.
3.3. Boronic acid test
Phenylboronic acid acts as an inhibitor for KPC carbapenemases and class A and C beta-
lactamases. The boronic acid test has been proposed for the phenotypic detection of KPC-
producers because it is easier to perform than the DDST and also presents less false positive
results because of the presence of ESBLs or AmpC beta-lactamases [29-31].
3.3.1. Procedure
Step 1: Make a 0.5 McFarland bacterial suspension.
Step 2: Inoculate with a sterile cotton swab and place two meropenem discs (Figure 5).
Figure 4. Interpretation of the imipenem-EDTA synergy test. (-): Negative; (+): Positive. Note that the upper left isolate
is negative for MBL production but shows positive D-test between imipenem and ceftazidime indicating for the pres‐
ence of inducible AmpC beta-lactamases (The D-test is described in paragraph 3.6).
Step 3: Add 20 μl of phenylboronic acid 20 g/L on one of the two meropenem discs.
Step 4: Incubate at 37oC for 18-24h.
3.3.2. Interpretation
In case of KPC production, the phenylboronic acid that has been added to the second mero‐
penem disc will block the hydrolytic activity of the enzyme. As a consequence, the second disc
will have a larger inhibition halo. The test is considered positive when the inhibition zone of
the meropenem+phenylboronic acid is ≥ 5mm larger than the inhibition zone of meropenem
alone (Figure 6).
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Figure 6. Interpretation of the boronic acid test. (+): Positive; (-): Negative.
3.4. Hodge test
The Hodge test is used to reveal carbapenemase production [32]. This is achieved by inocu‐
lating the study isolate together with a carbapenem-susceptible indicator strain and evaluating
the distortion of the indicator strain’s inhibition zone because of carbapenemase production
by the study isolate. Despite its usefulness, this test presents a disadvantage: it detects the
presence of carbapenemases only, without being able to discriminate between different
carbapenemase types (KPC or MBLs).
3.4.1. Procedure
Step 1: Make a 0.5 McFarland suspension of the indicator strain (for example E. coli ATCC
25922).
Figure 5. Preparation of the boronic acid test.
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Step 2: Inoculate with a sterile cotton swab and place a carbapenem disc at the center of the
plate.
Step 3: Streak 3-5 colonies of the test isolate from the center to the periphery of the plate (Figure
7).
Step 4: Incubate at 37oC for 18-24h.
Figure 7. Preparation of the Hodge test.
3.4.2. Interpretation
The presence of a distorted inhibition zone due to growth of the indicator strain toward the
carbapenem disc is interpreted as a positive result (Figure 8). This occurs due to carbapenemase
production by the study isolate. Uncertain results need to be confirmed by other tests or
molecular methods.
3.5. Combination meropenem disc test
This test is a combination of the EDTA and the boronic acid test in a single plate and has been
introduced in Greece after the emergence of Gram negative isolates co-producing KPC and
MBL carbapenemases [33-37]. The advantage of the test is that it discriminates between
carbapenem-susceptible, KPC-producing, MBL-producing and double-carbapenemase-
producing bacteria.
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3.5.1. Procedure
Step 1: Make a 0.5 McFarland bacterial suspension.
Step 2: Inoculate with a sterile cotton swab and place four meropenem discs (Figure 9).
Step 3: Add 10 μl EDTA 0.1 M on the second disc, 20 μl of phenylboronic acid 20 g/L on the
third disc and 20 μl of phenylboronic acid 20 g/L+10 μl EDTA 0.1 M on the fourth disc.
Step 4: Incubate at 37oC for 18-24h.
Figure 9. Preparation of the combination meropenem disc test.
3.5.2. Interpretation
The interpretation of the combination meropenem disc test is based on the comparison
between the inhibition zones of the four meropenem discs as presented in Figure 10. If no
carbapenemase is present, the zone diameters of the discs where inhibitors have been added
Figure 8. Interpretation of the Hodge test.
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will not present significant differences (≥5mm) from the meropenem disc alone. In case of KPC
production, an increase of ≥5mm in the discs that are supplemented with boronic acid will be
observed. MBL production will become evident by an increase of ≥5mm in the discs that are
supplemented with EDTA. In case of a KPC+MBL-producer, the fourth disc will present the
larger zone diameter of all. The EDTA-supplemented and boronic acid-supplemented discs
may or may not have a ≥5mm larger zone diameter than that of the meropenem disc alone.
Figure 10. Interpretation of the combination meropenem disc test.
Recently, a novel variation of this test has been proposed [38] for surveillance cultures from
rectal swabs. The same principle is generally followed, except that each swab is initially
suspended in 1 ml sterile saline by rotating and agitating it to release the microorganisms.
Afterwards, the suspension is cultured onto McConkey agar using a different swab. This
method allows the identification and differentiation of carbapenemase-producing Enterobac‐
teriaceae (Figure 11) directly at patient admission.
Figure 11. Application of the combination meropenem disc test for the direct differentiation of carbapenemase-pro‐
ducing Enterobacteriaceae in rectal swabs.
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3.6. D-test
The D-test is used for the detection of inducible AmpC beta-lactamases [39]. An antibiotic is
used as an inducer for AmpC production (imipenem or cefoxitin) whereas others are used as
substrates (ceftazidime, cefotaxime, piperacillin/tazobactam).
3.6.1. Procedure
Step 1: Make a 0.5 McFarland bacterial suspension.
Step 2: Inoculate with a sterile cotton swab and place an imipenem disc.
Step 3: Place substrate discs (for example ceftazidime and piperacillin/tazobactam) near the
imipenem disc as shown in Figure 12.
Step 4: Incubate at 37oC for 18-24h.
Figure 12. Preparation of a D-test.
3.6.2. Interpretation
The test is positive when a D-shaped inhibition zone is observed for one of the substrate discs
(Figure 13) because of the imipenem-mediated induction of the AmpC production and the
subsequent inactivation of the substrate antibiotic by the beta-lactamase. An important
advantage of the test is that it can be easily incorporated within any routine antibiogram as
shown in Figure 14.
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3.7. CCCP test
CCCP (Carbonyl cyanide m-chlorophenyl hydrazone) is an efflux pump inhibitor that can
be added in Mueller-Hinton agar during its preparation. The test is used to detect efflux
pump overexpression that contributes to or determines carbapenem resistance in the study
isolate [40].
Figure 13. Interpretation of the D-test.
Figure 14. Incorporation of the D-test in a common antibiogram.
3.7.1. Procedure
Step 1: Prepare agar plates containing CCCP at a concentration of 12.5 μM.
Step 2: Make a 0.5 McFarland bacterial suspension.
Step 3: Inoculate with a sterile cotton swab on a CCCP-supplemented plate and in parallel on
a CCCP-free plate. For economy reasons, two isolates may be inoculated on the same plate as
shown in Figure 15.
Step 4: Place a meropenem disc on both plates for each inoculation.
Step 5: Incubate at 37oC for 18-24h.
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Figure 15. Preparation of the CCCP test.
3.7.2. Interpretation
The test is considered positive when synergy between meropenem and CCCP is observed on
the CCCP-supplemented plate (Figure 16).
Figure 16. Interpretation of the CCCP test. Isolate 1 is inoculated on the upper side and isolate 2 is inoculated on the
lower side of the plates. (+): Positive; (-): Negative.
4. Molecular methods
Genetic methods for the detection of resistance genes are based on nucleic acid hybridization
and amplification. Therefore, the knowledge of specific primers (amplification nucleotides)
and probes (labeled single-stranded ologonucleotides) is necessary in order to detect the
genetic target of interest. The technique used depends on the type of resistance that is sus‐
pected. A simple polymerase chain reaction (PCR) may be applied searching for a gene that
confers a certain level of resistance when it is expressed. This is the case for example, of genes
encoding for antibiotic-inactivating enzymes. In Tables 2 and 3, primers for the detection of
aminoglycoside or fluorquinolone resistance-conferring enzymes and beta-lactamases are
shown, respectively.
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Gene Primers (5’- 3’) Product size Reference
aac(6’)-Ia ATGAATTATCAAATTGTG 558 bp [41]
TTACTCTTTGATTAAACT
aac(6’)-Ic CTACGATTACGTCAACGGCTGC 130 bp [42]
TTGCTTCGCCCACTCCTGCACC
aac(3)-Ia ACCTACTCCCAACATCAGCC 169 bp [43]
ATATAGATCTCACTACGCGC
aac(3)-Ic GATGATCTCTACTCAAACC 472 bp [44]
TTAGGCAGCAGGTTGAGG
aac(3)-IV GTTACACCGGACCTTGGA 675 bp [45]
AACGGCATTGAGCGTCAG
aphA-3 GGGACCACCTATGATGTGGAACG 595 bp [46]
CAGGCTTGATCCCCAGTAAGTC
aph(3’)-Via ATACAGAGACCACATACAGT 235 bp [47]
GGACAATCAATAATAGCAAT
aad(2’’)-Ia ATGTTACGCAGCAGGGCAGTCG 188 bp [48]
CGTCAGATCAATATCATCGTGC
aph(3’)-IIIa GGCTAAAATGAGAATATCACCGG 523 bp [49,50]
CTTTAAAAAATCATACAGCTCGCG
ant(4’)-Ia CAAACTGCTAAATCGGTAGAAGCC 294 bp [49,50]
GGAAAGTTGACCAGACATTACGAACT
strA-strB TATCTGCGATTGGACCCTCTG 519 bp [51]
CATTGCTCATCATTTGATCGGCT
armA AGGTTGTTTCCATTTCTGAG 590 bp [52]
TCTCTTCCATTCCCTTCTCC
rmtA CTAGCGTCCATCCTTTCCTC 635 bp [53]
TTTGCTTCCATGCCCTTGCC
rmtB ATGAACATCAACGATGCCCT 769 bp [54]
CCTTCTGATTGGCTTATCCA
gyrA
(A. baumannii)
AAATCTGCCCGTGTCGTTGGT 343 bp [55]
GCCATACCTACGGCGATACC
gyrA (E. coli) ACGTACTAGGCAATGACTGG 190 bp [56]
AGAAGTCGCCGTCGATAGAAC
qnrA TCAGCAAGAGGATTTCTCA 627 bp [57]
GGCAGCACTATTACTCCCA
Qnr CCGTATGGATATTATTGATAAAG 661 bp [58]
CTAATCCGGCAGCACTATTA
Table 2. Primers used for the detection of aminoglycoside and quinolone resistance determinants.
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Gene Primers (5’- 3’) Product size Reference
blaSHV GGTTATGCGTTATATTCGCC 867 bp [59]
TTAGCGTTGCCAGTGCTC
blaTEM ATGAGTATTCAACATTTCCG 867 bp [59]
CTGACAGTTACCAATGCTTA
blaCTX-M CGCTTTGCGATGTGCAG 550 bp [60]
ACCGCGATATCGTTGGT
blaCTX-M-2 ATGATGACTCAGAGCATTCG 884 bp [61]
TTATTGCATCAGAAACCGTG
blaCTX-M-9 GTGACAAAGAGAGTGCAACGG 857 bp [62]
ATGATTCTCGCCGCTGAAGCC
blaCTX-M-10 GCTGATGAGCGCTTTGCG 684 bp [63]
TTACAAACCGTTGGTGACG
blaGES/IBC GTTTTGCAATGTGCTCAACG 371 bp [64]
TGCCATAGCAATAGGCGTAG
blaPER-1 ATGAATGTCATTATAAAAGC 926 bp [65]
AATTTGGGCTTAGGGCAAGAAA
blaPER-2 CGCTTCTGCTCTGCTGAT 469 bp [66]
GGCAGCTTCTTTAACGCC
blaPSE ACCGTATTGAGCCTGATTTA 321 bp [67]
ATTGAAGCCTGTGTTTGAGC
blaTLA-1 TCTCAGCGCAAATCCGCG 974 bp [68]
CTATTTCCCATCCTTAACTAG
blaVEB-1 CGACTTCCATTTCCCGATGC 643 bp [69]
GGACTCTGCAACAAATACGC
blaKPC TGTCACTGTATCGCCGTC 331 bp [70]
TATTTTTCCGAGATGGGTGAC
blaSME-1 AACGGCTTCATTTTTGTTTAG 830 bp [71]
GCTTCCGCAATAGTTTTATCA
blaIMP CTACCGCAGCAGAGTCTTTG 587 bp [72]
AACCAGTTTTGCCTTACCAT
blaIMP-1 ATGAGCAAGTTATCTGTATTC 741 bp [73]
TTAGTTGCTTGGTTTTGATGG
blaIMP-2 ATGAAGAAATTATTTGTTTTATG 741 bp [73]
TTAGTTACTTGGCTGTGATG
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Gene Primers (5’- 3’) Product size Reference
blaVIM TCTACATGACCGCGTCTGTC 748 bp [74]
TGTGCTTTGACAACGTTCGC
blaVIM-1 GTTAAAAGTTATTAGTAGTTTATTG 799 bp [73]
CTACTCGGCGACTGAGC
blaVIM-2 ATGTTCAAACTTTTGAGTAAG 801 bp [73]
CTACTCAACGACTGAGCG
blaSPM-1 CCTACAATCTAACGGCGACC 649 bp [75]
TCGCCGTGTCCAGGTATAAC
blaNDM-1 GGTTTGGCGATCTGGTTTTC 621 bp [76]
CGGAATGGCTCATCACGATC
blaOXA-1 CCAAAGACGTGGATG 540 bp [77]
GTTAAATTCGACCCCAAGTT
blaOXA-10 CGTGCTTTGTAAAAGTAGCAG 652 bp [78]
CATGATTTTGGTGGGAATGG
blaOXA-23 CCTCAGGTGTGCTGGTTATTC 513 bp [79]
CCCAACCAGTCTTTCCAAAA
blaOXA-24 TTCCCCTAACATGAATTTGT 1020 bp [80]
GTACTAATCAAAGTTGTGAA
Table 3. Primers used for the detection of beta-lactamases frequently encountered among Gram negative pathogens.
In cases in which resistance depends upon the expression level (overexpression or downre‐
gulation) of the gene, real time Reverse Transcriptase-PCR (rt RT-PCR) is used to detect not
only the presence, but also the mRNA expression of the gene. The results are consequently
confronted with the expression level of the same gene in a control strain. This technique is
useful for the study of the expression of specific porins and efflux pumps (primers and probes
for such resistance determinants in P. aeruginosa are shown in Table 4).
Gene Primers (5’- 3’) Reference
ampC CGCCGTACAACCGGTGAT [81]
CGGCCGTCCTCTTTCGA
probe [DFAM]TCAGCCTGAAAGGAGAACCGCATTACTTC[DTAM]
OprD CTACGGCTACGGCGAGGAT [81]
GACCGGACTGGACCACGTACT
probe [DFAM]CACCACGAAACCAACCTCGAAGCC[DTAM]
mexA AACCCGAACAACGAGCTG [81]
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Gene Primers (5’- 3’) Reference
ATGGCCTTCTGCTTGACG
probe [DFAM]CATGTTCGTTCACGCGCAGTTG[DTAM]
mexC GGAAGAGCGACAGGAGGC [81]
CTGCACCGTCAGGCCCTC
probe [DFAM]CCGAAATGGTGTTGCCGGTG[DTAM]
mexE TACTGGTCCTGAGCGCCT [81]
TCAGCGGTTGTTCGATGA
probe [DFAM]CGGAAACCACCCAAGGCATG[DTAM]
mexX GGCTTGGTGGAAGACGTG [81]
GGCTGATGATCCAGTCGC
probe [DFAM]CCGACACCCTGCAGGGCC[DTAM]
Table 4. Primers and probes used in real-time RT PCR for the determination of the expression levels for specific
resistance mechanisms in P. aeruginosa.
Finally, sequencing [82-84] of the PCR product allows its confrontation with the already known
gene sequences that are available in genetic databases. This can lead to the detection of
mutations or to the characterization and classification of the gene within a genetic family.
5. Conclusion
There are several benefits and limitations using either phenotypic or molecular methods for
the detection of resistance mechanisms in Gram negative pathogens. Phenotypic tests require
bacteria in pure culture from a clinical sample thus needing 24-48h to obtain a final result.
Molecular techniques on the other hand, can be performed directly with clinical speciments
reducing significantly the procedure time.
The detection of low-level resistance is by definition problematic using phenotypic tests thus
interpretation problems may appear. In such cases, molecular techniques are an option for
clarifying the possible involvement of any known resistance mechanism.
Moreover, genetic detection gives a definite answer for the presence or not of specific resistance
determinants within a study isolate (a specific beta-lactamase for example) whereas this is not
possible with the phenotypic tests which provide only general information about the resistance
mechanisms involved.
Genetic assays however, present also some major limitations: (i) It is possible to screen
exclusively for known mechanisms and for one gene at the time (unless a multiplex PCR assay
[85-88] can be applied) and; (ii) their cost is high and becomes higher when screening for
multiple resistance determinants.
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Consequently, the combined and rational use of the available methodologies seems to be the
optimal solution for the cost-effective detection of resistance mechanisms in Gram negative
pathogens by the Clinical Microbiology laboratory.
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